SCHEMBL3076047

SCHEMBL3076047

O=C(NC12CC3CC(CC(C3)C1)C2)c1cnn(-c2ccccc2)c1NCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.51
EPHX2 P34913 1/20 0.51
CNR2 P34972 8/20 0.49
CNR1 P21554 5/20 0.49
FAAH O00519 3/20 0.49
CASR P41180 5/20 0.48
HPGD P15428 2/20 0.47
MAPT P10636 2/20 0.46
HTT P42858 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
ALOX12 P18054 1/20 0.46
ATM Q13315 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063433 0.92 TSHR (0.49) MAPK1EPHX2CNR2CNR1FAAH
SCHEMBL3070635 0.88 CNR2 (0.48) CNR2CNR1FAAHCASRHPGD
SCHEMBL3067236 0.87 CASR (0.48) EPHX2CNR2CNR1FAAHCASR
SCHEMBL3074521 0.86 CNR2 (0.49) CNR2CNR1FAAHCASRHPGD
SCHEMBL3080921 0.86 CNR2 (0.48) CNR2CNR1FAAHCASRHPGD
SCHEMBL3057487 0.85 CNR2 (0.50) CNR2CNR1CASR
SCHEMBL3063101 0.83 CNR2 (0.49) EPHX2CNR2CNR1FAAHCASR
SCHEMBL3076046 0.82 HSD11B1 (0.55) EPHX2CNR2CNR1HPGD
SCHEMBL3066175 0.82 CNR2 (0.52) CNR2CNR1FAAHCASRHPGD
SCHEMBL3062700 0.82 CNR2 (0.49) CNR2CNR1FAAHCASRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2178845-B1 INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE HOFFMANN LA ROCHE (CH) 2013-06-19 EP claimed
EP-2178845-A2 INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE F. Hoffmann-Roche AG (CH) 2010-04-28 EP claimed
WO-2009010416-A2 INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO claimed
EP-2178845-B1 INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE HOFFMANN LA ROCHE (CH) 2013-06-19 EP disclosed
US-7790711-B2 Inhibitors of 11β-Hydroxysteroid Dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-09-07 US disclosed
EP-2178845-A2 INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE F. Hoffmann-Roche AG (CH) 2010-04-28 EP disclosed
US-20090023709-A1 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase GILLESPIE PAUL 2009-01-22 US disclosed
WO-2009010416-A2 INHIBITORS OF 11B-HYDROXYSTEROID DEHYDROGENASE F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023709-A1 Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase HSD17B1, HSD17B2, HSD11B1 MAPK1 2678/4885EPHX2 576/4885CNR2 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.